New meta-substituted thiazolidinone compounds are polo-like kinase inhibitors useful to treat cancers, autoimmune-, cardiovascular-, infectious-, nephrological-, nephrological- and neurodegenerative-diseases

Meta-substituted thiazolidinone compounds (I), their solvates, hydrates, diastereomers, enantiomers and salts are new. Meta-substituted thiazolidinone compounds of formula (I), their solvates, hydrates, diastereomers, enantiomers and salts are new. T 1>, T 3>-CH= or -N=; T 2>T 1> or (-CF)=; U 1>e.g. -N=; R 1>1-3C alkyl or cyclopropyl (both optionally substituted with halo); R 2>1-3C alkyl, 3-4C alkenyl, 3-4C alkynyl or cyclopropyl (all optionally substituted with CN, cyclopropyl, ethynyl or halo); R 3>e.g. K 1>; and K 1>1-3C alkyl or 2-4C alkenyl (both optionally substituted). Full definitions are given in the DEFINITIONS - Full Definitions section. Independent claims are also included for: (1) substituted thiazolidinone compounds of formula (II) or (IV), their solvates, hydrates, diastereomers, enantiomers and salts as intermediates for preparing (I); and (2) the preparation of (I). [Image] [Image] ACTIVITY : Cytostatic; Immunosuppressive; Antipsoriatic; Endocrine-Gen.; Neuroprotective; Cardiovascular-Gen.; Antiarteriosclerotic; Vasotropic; Antimicrobial; Antiparasitic; Nephrotropic; Anticonvulsant; Nootropic; Antiparkinsonian; Virucide; Antiinflammatory; Hepatotropic; Anti-HIV. MECHANISM OF ACTION : Polo-like kinase inhibitor. Die Erfindung betrifft Thiazolidinone der allgemeinen Formel (I) DOLLAR F1 sowie deren Herstellung und Verwendung als Inhibitoren der Polo Like Kinase (Plk) zur Behandlung verschiedener Erkrankungen.